Literature DB >> 9713462

Mutations of ras genes are relatively frequent in Japanese prostate cancers: pointing to genetic differences between populations.

T Shiraishi1, T Muneyuki, K Fukutome, H Ito, T Kotake, M Watanabe, R Yatani.   

Abstract

Point mutations of the ras gene family are thought to be involved in the development of a variety of human tumors. However, it remains unknown whether the ras gene might play a key role in prostate carcinogenesis. We therefore analysed Ki-,N- and H-ras gene mutations in a series of 81 Japanese prostate cancers using PCR-SSCP analysis and Mutant-Allele-Specific Amplification (MASA) method. Mutated as genes were detected in 20 of the 81 samples (24%); three of 22 latent, one of five stage B, four of 14 stage C and 12 of 40 stage D cancers. Of the twenty as gene mutations, 13 were in Ki-ras (codon 12), five in H-ras codon 61 and two H-ras codon 13. The observed frequency of ras gene mutations was higher than that reported in the literature for some non-Japanese prostate cancers, suggesting the possibility of genetic differences between populations.

Entities:  

Mesh:

Year:  1998        PMID: 9713462

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  12 in total

1.  Combination analysis of genetic alterations and cell proliferation in small intestinal carcinomas.

Authors:  T Muneyuki; M Watanabe; M Yamanaka; S Isaji; Y Kawarada; R Yatani
Journal:  Dig Dis Sci       Date:  2000-10       Impact factor: 3.199

2.  The Raf/MEK/extracellular signal-regulated kinase 1/2 pathway can mediate growth inhibitory and differentiation signaling via androgen receptor downregulation in prostate cancer cells.

Authors:  Seung-Keun Hong; Jin-Hwan Kim; Ming-Fong Lin; Jong-In Park
Journal:  Exp Cell Res       Date:  2011-08-16       Impact factor: 3.905

Review 3.  Behavioral genetics of the depression/cancer correlation: a look at the Ras oncogene family and the 'cerebral diabetes paradigm'.

Authors:  Janet K Brewer
Journal:  J Mol Neurosci       Date:  2008-06-18       Impact factor: 3.444

4.  AKT upregulates B-Raf Ser445 phosphorylation and ERK1/2 activation in prostate cancer cells in response to androgen depletion.

Authors:  Seung-Keun Hong; Joseph H Jeong; Andrew M Chan; Jong-In Park
Journal:  Exp Cell Res       Date:  2013-05-20       Impact factor: 3.905

5.  Mutation status of somatic EGFR and KRAS genes in Chinese patients with prostate cancer (PCa).

Authors:  Meng Fu; Wei Zhang; Ling Shan; Jian Song; Donghao Shang; Jianming Ying; Jimao Zhao
Journal:  Virchows Arch       Date:  2014-03-05       Impact factor: 4.064

6.  The role of polycyclic aromatic hydrocarbon-DNA adducts in inducing mutations in mouse skin.

Authors:  Dhrubajyoti Chakravarti; Divya Venugopal; Paula C Mailander; Jane L Meza; Sheila Higginbotham; Ercole L Cavalieri; Eleanor G Rogan
Journal:  Mutat Res       Date:  2007-09-07       Impact factor: 2.433

7.  Prostate tumours from an Asian population: examination of bax, bcl-2, p53 and ras and identification of bax as a prognostic marker.

Authors:  S J Chia; W Y Tang; J Elnatan; W M Yap; H S Goh; D R Smith
Journal:  Br J Cancer       Date:  2000-09       Impact factor: 7.640

8.  MicroRNA-34a regulates WNT/TCF7 signaling and inhibits bone metastasis in Ras-activated prostate cancer.

Authors:  Wei-Yu Chen; Shih-Yang Liu; Yung-Sheng Chang; Juan Juan Yin; Hsiu-Lien Yeh; Tarek H Mouhieddine; Ola Hadadeh; Wassim Abou-Kheir; Yen-Nien Liu
Journal:  Oncotarget       Date:  2015-01-01

Review 9.  The molecular basis for ethnic variation and histological subtype differences in prostate cancer.

Authors:  Yang Zong; Andrew S Goldstein; Jiaoti Huang
Journal:  Sci China Life Sci       Date:  2013-07-13       Impact factor: 6.038

10.  BRAF activation initiates but does not maintain invasive prostate adenocarcinoma.

Authors:  Joseph H Jeong; Zhenxiong Wang; Alexander S Guimaraes; Xuesong Ouyang; Jose L Figueiredo; Zhihu Ding; Shan Jiang; Isil Guney; Gyeong Hoon Kang; Eyoung Shin; William C Hahn; Massimo F Loda; Cory Abate-Shen; Ralph Weissleder; Lynda Chin
Journal:  PLoS One       Date:  2008-12-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.